# Product Maturity Assessment

Last updated: 2026-06-11

## Scoring Method

Scores use a 1–5 scale:

- **1 — Conceptual:** direction exists, but capability is not implemented.
- **2 — Early:** partial implementation or limited workflow evidence.
- **3 — Functional MVP:** implemented and internally coherent, but important validation or operational gaps remain.
- **4 — Adoption-ready:** strong implementation plus representative clinician validation and manageable operational gaps.
- **5 — Production-proven:** validated in sustained real-world use with production controls and measured outcomes.

Scores distinguish four evidence levels:

1. **Implemented capability** — present in the current repository.
2. **Simulated validation** — exercised through persona, comparative workflow, or synthetic caseload review.
3. **Real clinician validation** — observed with representative clinicians and cases.
4. **Production/pilot readiness** — includes operational, privacy, security, support, instrumentation, and deployment readiness.

Implementation and simulation do not imply clinician validation or pilot readiness.

## Maturity Scores

| Area | Score | Evidence level | Rationale |
| --- | ---: | --- | --- |
| Product positioning and identity | **4.0** | Implemented | Clinical Continuity Platform naming, tagline, patient-centered terminology, and the maintained-understanding thesis now align with product behavior. Market resonance remains unvalidated. |
| Deterministic clinical reasoning foundation | **4.0** | Implemented; internally tested | Reasoning, operational prioritization, continuity, progression, reassessment, and reconciliation capabilities are substantial and stable. Real-clinical accuracy remains unproven. |
| Longitudinal continuity | **3.8** | Implemented; simulated | The platform maintains current meaning across visits and separates current truth from history. Correction behavior and real-world longitudinal comprehension still need validation. |
| Visit Briefing usability | **3.8** | Implemented; simulated | Hierarchy refinement, Session Focus, Attention Required, Supporting Evidence, Why This Changed, Progression Constraint, Progress Evidence, and Reassessment Summary materially strengthen orientation and execution. Real-clinician speed and comprehension are not established. |
| Explainability and provenance | **3.5** | Implemented; simulated | Supporting Evidence and Why This Changed provide local, deterministic explanations. Provenance hardening, source correction, and rejection workflows remain incomplete. |
| Progression and reassessment support | **3.7** | Implemented; simulated | Progression Constraint, Progress Evidence, and Reassessment Summary support a coherent progression story. Clinician agreement and real reassessment reuse remain unvalidated. |
| Workflow reuse | **3.2** | Implemented assets; simulated comparative validation | Maintained Understanding plus Progress Evidence performed well for reassessment, physician update, and care conference. QA remains verification-dependent, and reusable outputs are not yet fully productized. |
| Patients page / caseload usability | **3.4** | Implemented; 80-patient simulation | System Views, clinical-priority sorting, status, current focus, and recent change shift Patients from record browsing to prioritization. The legacy filter, status clarity, and recent-change quality need cleanup and clinician testing. |
| Clinical Translation Workspace | **3.0** | Implemented organization; limited simulation | Case Details is reorganized around caregiver, equipment, patient, family, clinical communication, and documentation/QA use cases. Content remains dense and audience-specific reusable outputs are not yet mature. |
| Mobile and field-context readiness | **2.4** | Partial implementation; limited simulation | Responsive work exists, but representative devices, field conditions, interruption patterns, and read-aloud access are not fully tested. |
| Clinician correction and governance UX | **2.2** | Partial | Deterministic authority and immutable history are defined, but the end-to-end clinician correction, rejection, and provenance workflow needs specification and validation. |
| Real clinician validation | **1.5** | Not established | Current evidence is predominantly internal, simulated, persona-based, or synthetic-caseload testing. It must not be treated as clinician proof. |
| Pilot / production readiness | **1.8** | Not ready | Privacy, security, instrumentation, support, deployment operations, representative workflow validation, and controlled-pilot criteria are incomplete. |

## Overall Maturity Assessment

The Clinical Continuity Platform is a **functional and strategically coherent MVP with substantial implemented workflow depth**. Its product identity now matches its behavior, and its strongest surfaces address caseload prioritization, visit preparation, progression understanding, evidence-linked trust, reassessment reuse, and clinical translation.

The main maturity gap is no longer basic capability breadth. It is evidence and operational readiness: whether real clinicians can rapidly orient, agree with maintained conclusions, identify errors, correct the system, reuse outputs safely, and do so on mobile devices in field conditions.

## Readiness Judgments

### MVP capability readiness: Yes, with boundaries

The platform is sufficiently implemented for focused formative testing of:

- Patients page triage;
- Visit Briefing orientation;
- Session Focus usefulness;
- progression and reassessment explanations;
- Clinical Translation Workspace usefulness; and
- correction/provenance concepts.

### Real-clinician validation readiness: Yes

The product is ready for controlled, non-production formative studies using representative cases. Testing should measure comprehension, disagreement, correction behavior, reconstruction burden, and workflow fit—not merely preference.

### Pilot readiness: No

A pilot should wait for:

- real-clinician formative findings;
- correction workflow and provenance hardening;
- mobile field testing;
- privacy, security, support, and instrumentation review; and
- explicit pilot safety and success criteria.

### Production readiness: No

No current evidence supports production-readiness claims, clinical outcome claims, or measured time-savings claims.
